MedPath

Effects of Remote Ischemic Conditioning on Cerebral Hemodynamics in Patients With Ischemic Stroke

Not Applicable
Recruiting
Conditions
Acute Ischemic Stroke
Registration Number
NCT05915832
Lead Sponsor
Yi Yang
Brief Summary

The purpose of this study is to determine the impact of remote ischemic conditioning on cerebral hemodynamics in patients with ischemic stroke.

Detailed Description

Current studies have shown that remote ischemic conditioning can activate neuronal signals and humoral factors, increase cerebral perfusion and promote neurological recovery in patients with ischemic stroke.The purpose of this study was to investigate the effect of remote ischemic conditioning on cerebral hemodynamics in patients with acute ischemic stroke.

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
120
Inclusion Criteria
  1. Age ≥18 years, <80 years, both sex;
  2. Patients with a clinically definite diagnosis of acute ischemic stroke who are able to commence RIC treatment within 72 hours of stroke onset;
  3. Baseline National Institute of Health Stroke Scale (NIHSS) score<25;
  4. Pre-onset modified Rankin Scale (mRS) score ≤ 1;
  5. Glasgow Coma Scale score ≥8;
  6. Signed and dated informed consent is obtained.
Exclusion Criteria
  1. Patients who have undergone thrombolytic therapy or endovascular therapy;
  2. Inability to cooperate sufficiently to complete the cerebral autoregulation examination (e.g., due to a condition such as agitation, drowsiness, arrhythmia, insufficient bilateral temporal bone windows, etc.) during the recording;
  3. Presence of other intracranial lesions, such as cerebrovascular malformations, cerebral venous thrombosis, tumors, and other brain lesions;
  4. severe hepatic and renal dysfunction or failure;
  5. Patients with hematological disease, abnormal coagulation function, bleeding tendency, and platelet <100×10^9/L;
  6. Individuals who had contraindication of remote ischemic conditioning, such as severe soft tissue injury, fracture or vascular injury in the upper extremities, venous thrombosis in the acute or subacute stage of upper extremities, arterial occlusive disease, subclavian artery stenosis ≥ 50%, or subclavian steal syndrome;
  7. pregnant or lactating women;
  8. Previous RIC treatment or similar treatment;
  9. Patients with a life expectancy of less than 3 months or patients who are unable to complete the study for other reasons;
  10. unwillingness to be followed up or poor treatment adherence;
  11. Individuals who are participating in other clinical studies, have participated in other clinical studies within 3 months prior to enrollment, or have participated in this research;
  12. Other conditions that the investigator considers inappropriate for enrollment.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Primary Outcome Measures
NameTimeMethod
Cerebral autoregulation at 7 days0 - 7 days

Difference in Cerebral autoregulation at 7 days after RIC/sham-RIC between two groups. Phase difference (PD) in degree can therefore serve as a useful tool in the evaluation of cerebral autoregulation. Continuous cerebral blood flow velocities (CBFV) in cm/s of bilateral middle cerebral artery will be assessed noninvasively using transcranial Doppler. Spontaneous arterial blood pressure (ABP) in mmHg will be simultaneously recorded using a servo-controlled plethysmograph on the left or right middle finger with an appropriate finger cuff size. Data on CBFV and ABP were processed using MATLAB using scripts developed by the research team. PD was then derived from transfer function analysis to assess the dynamic association between CBFV and ABP.

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

First Hospital of Jilin University

🇨🇳

Changchun, Jilin, China

First Hospital of Jilin University
🇨🇳Changchun, Jilin, China
Yi Yang, MD, PhD
Contact
18186870008
doctoryangyi@163.com
Zhenni Guo, MD,PhD
Contact
18186872986
zhen1ni2@163.com

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.